Sentynl Drug Patent Portfolio
Sentynl owns 3 orange book drugs protected by 6 US patents Given below is the list of Sentynl's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7838531 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis | 26 Jul, 2029 | Active |
| US7504095 | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency | 09 Apr, 2029 | Active |
| US8828356 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis | 17 Oct, 2025 | Expired |
| US6759059 | Fentanyl composition for the treatment of acute pain | 24 Sep, 2019 | Expired |
| US6761910 | Pharmaceutical composition for the treatment of acute disorders | 24 Sep, 2019 | Expired |
| US7910132 | Pharmaceutical composition for the treatment of acute disorders | 24 Sep, 2019 | Expired |
Latest Legal Activities on Sentynl's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sentynl.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Eligible | 08 Jul, 2025 | US7504095 |
| FDA Final Eligibility Letter | 20 May, 2025 | US7504095 |
| Information Disclosure Statement (IDS) Filed | 20 May, 2025 | US7504095 |
| Notice of Final Determination -Election Required | 09 Apr, 2025 | US8828356 |
| Notice of Final Determination -Election Required | 09 Apr, 2025 | US7838531 |
| FDA Final Eligibility Letter | 13 Jan, 2025 | US8828356 |
| FDA Final Eligibility Letter | 13 Jan, 2025 | US7838531 |
| Requirement for information sent under 37 CFR 1.750 | 29 Jul, 2024 | US8828356 |
| Interim Patent Term Extension Granted | 29 Jul, 2024 | US8828356 |
| Interim Patent Term Extension Granted | 24 Jul, 2024 | US7838531 |
| Requirement for information sent under 37 CFR 1.750 | 08 Jul, 2024 | US7838531 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US7504095 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2024 | US7838531 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Jan, 2024 | US8828356 |
| transaction for FDA Determination of Regulatory Review Period | 27 Dec, 2023 | US7838531 |
Sentynl's Family Patents
Sentynl Drug List
Given below is the complete list of Sentynl's drugs and the patents protecting them.
1. Abstral
Abstral is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6759059 | Fentanyl composition for the treatment of acute pain |
24 Sep, 2019
(6 years ago)
| Expired |
| US6761910 | Pharmaceutical composition for the treatment of acute disorders |
24 Sep, 2019
(6 years ago)
| Expired |
| US7910132 | Pharmaceutical composition for the treatment of acute disorders |
24 Sep, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abstral's drug page
2. Nulibry
Nulibry is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7504095 | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
09 Apr, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nulibry's drug page
3. Zokinvy
Zokinvy is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7838531 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
26 Jul, 2029
(3 years from now)
| Active |
| US8828356 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
17 Oct, 2025
(4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zokinvy's drug page